Urinary proteomics can define distinct diagnostic inflammatory arthritis subgroups

Siebert, S. , Porter, D., Paterson, C., Hampson, R., Gaya, D., Latosinska, A., Mischak, H., Schanstra, J., Mullen, W. and McInnes, I. (2017) Urinary proteomics can define distinct diagnostic inflammatory arthritis subgroups. Scientific Reports, 7, 40473. (doi:10.1038/srep40473) (PMID:28091549) (PMCID:PMC5320079)

[img]
Preview
Text
135849.pdf - Published Version
Available under License Creative Commons Attribution.

868kB

Abstract

Current diagnostic tests applied to inflammatory arthritis lack the necessary specificity to appropriately categorise patients. There is a need for novel approaches to classify patients with these conditions. Herein we explored whether urinary proteomic biomarkers specific for different forms of arthritis (rheumatoid arthritis (RA), psoriatic arthritis (PsA), osteoarthritis (OA)) or chronic inflammatory conditions (inflammatory bowel disease (IBD)) can be identified. Fifty subjects per group with RA, PsA, OA or IBD and 50 healthy controls were included in the study. Two-thirds of these populations were randomly selected to serve as a training set, while the remaining one-third was reserved for validation. Sequential comparison of one group to the other four enabled identification of multiple urinary peptides significantly associated with discrete pathological conditions. Classifiers for the five groups were developed and subsequently tested blind in the validation test set. Upon unblinding, the classifiers demonstrated excellent performance, with an area under the curve between 0.90 and 0.97 per group. Identification of the peptide markers pointed to dysregulation of collagen synthesis and inflammation, but also novel inflammatory markers. We conclude that urinary peptide signatures can reliably differentiate between chronic arthropathies and inflammatory conditions with discrete pathogenesis.

Item Type:Articles
Additional Information:The sample collection and proteomics was funded by an investigator-initiated competitive research grant from Pfizer.
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:McInnes, Professor Iain and Mullen, Dr William and Mischak, Professor Harald and Gaya, Mr Daniel and Porter, Dr Duncan and Siebert, Dr Stefan and Paterson, Miss Caron
Authors: Siebert, S., Porter, D., Paterson, C., Hampson, R., Gaya, D., Latosinska, A., Mischak, H., Schanstra, J., Mullen, W., and McInnes, I.
College/School:College of Medical Veterinary and Life Sciences > Institute of Cardiovascular and Medical Sciences
College of Medical Veterinary and Life Sciences > Institute of Infection Immunity and Inflammation
College of Medical Veterinary and Life Sciences > School of Medicine, Dentistry & Nursing
Journal Name:Scientific Reports
Publisher:Nature Publishing Group
ISSN:2045-2322
ISSN (Online):2045-2322
Copyright Holders:Copyright © 2017 The Authors
First Published:First published in Scientific Reports 7: 40473
Publisher Policy:Reproduced under a Creative Commons License

University Staff: Request a correction | Enlighten Editors: Update this record

Project CodeAward NoProject NamePrincipal InvestigatorFunder's NameFunder RefLead Dept
690421Glasgow Molecular Pathology (GMP) NodeKarin OienMedical Research Council (MRC)MR/N005813/1ICS - EXPERIMENTAL THERAPEUTICS